Jeil Pharmaceutical Co Ltd Net Assets
Jeil Pharmaceutical Co Ltd net assets. Based on the latest financial reports, Jeil Pharmaceutical Co Ltd (271980) has net assets worth ₩253.26 Billion KRW (≈ $171.63 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩526.12 Billion ≈ $356.54 Million USD) and total liabilities (₩272.85 Billion ≈ $184.91 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 271980 net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩253.26 Billion |
| % of Total Assets | 48.14% |
| Annual Growth Rate | 4.39% |
| 5-Year Change | 50.0% |
| 10-Year Change | N/A |
| Growth Volatility | 14.57 |
Net Assets of Jeil Pharmaceutical Co Ltd (2017–2025)
Net assets of Jeil Pharmaceutical Co Ltd from 2017 to 2025. This chart illustrates how Jeil Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See 271980 net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Jeil Pharmaceutical Co Ltd (2017–2025)
The table below shows the annual net assets of Jeil Pharmaceutical Co Ltd from 2017 to 2025. For live market cap and overall valuation, see 271980 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩251.03 Billion ≈ $170.12 Million |
+14.46% |
| 2024-12-31 | ₩219.32 Billion ≈ $148.63 Million |
+39.66% |
| 2023-12-31 | ₩157.03 Billion ≈ $106.42 Million |
+0.92% |
| 2022-12-31 | ₩155.60 Billion ≈ $105.45 Million |
-7.02% |
| 2021-12-31 | ₩167.35 Billion ≈ $113.41 Million |
-2.98% |
| 2020-12-31 | ₩172.48 Billion ≈ $116.89 Million |
+1.43% |
| 2019-12-31 | ₩170.04 Billion ≈ $115.24 Million |
-8.05% |
| 2018-12-31 | ₩184.93 Billion ≈ $125.33 Million |
+3.90% |
| 2017-12-31 | ₩177.99 Billion ≈ $120.62 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jeil Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1774.5% over the analyzed period, potentially due to dividend distributions or operating losses.
Jeil Pharmaceutical Co Ltd Net Assets Breakdown (December 2025)
Jeil Pharmaceutical Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩240.41 Billion | 113.90% |
| Total Equity | ₩211.07 Billion | 100.00% |
Jeil Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Jeil Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BingEx Ltd
NASDAQ:FLX
|
$86.91 Million |
|
Tropical Canning (Thailand) Public Company Limited
BK:TC
|
$86.92 Million |
|
Shotspotter Inc
NASDAQ:SSTI
|
$86.92 Million |
|
Carlo Gavazzi Holding AG
SW:GAV
|
$86.94 Million |
|
Enablence Technologies Inc
V:ENA
|
$86.88 Million |
|
Stella Holdings Bhd
KLSE:5006
|
$86.87 Million |
|
Lotte Himart
KO:071840
|
$86.86 Million |
|
Brii Biosciences Limited
F:7SS
|
$86.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jeil Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 188,149,813,680 to 211,071,377,850, a change of 22,921,564,170 (12.2%).
- Net income of 23,383,972,880 contributed positively to equity growth.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩23.38 Billion | +11.08% |
| Other Changes | ₩-462.41 Million | -0.22% |
| Total Change | ₩- | 12.18% |
Book Value vs Market Value Analysis
This analysis compares Jeil Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.61x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.72x to 0.61x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩12106.81 | ₩8720.00 | x |
| 2018-12-31 | ₩12581.11 | ₩8720.00 | x |
| 2019-12-31 | ₩11635.35 | ₩8720.00 | x |
| 2020-12-31 | ₩11800.20 | ₩8720.00 | x |
| 2021-12-31 | ₩11515.67 | ₩8720.00 | x |
| 2022-12-31 | ₩10836.83 | ₩8720.00 | x |
| 2023-12-31 | ₩10882.20 | ₩8720.00 | x |
| 2024-12-31 | ₩12912.16 | ₩8720.00 | x |
| 2025-12-31 | ₩14353.84 | ₩8720.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jeil Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.08%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.12%
- • Asset Turnover: 1.11x
- • Equity Multiplier: 2.42x
- Recent ROE (11.08%) is above the historical average (-2.00%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.60% | 0.29% | 0.90x | 2.32x | ₩-16.73 Billion |
| 2018 | 1.02% | 0.30% | 1.56x | 2.18x | ₩-16.60 Billion |
| 2019 | -6.22% | -1.58% | 1.67x | 2.36x | ₩-27.59 Billion |
| 2020 | 4.01% | 1.00% | 1.69x | 2.38x | ₩-10.32 Billion |
| 2021 | -7.42% | -1.78% | 1.64x | 2.54x | ₩-29.29 Billion |
| 2022 | -8.29% | -1.81% | 1.58x | 2.89x | ₩-28.88 Billion |
| 2023 | 3.16% | 0.69% | 1.49x | 3.07x | ₩-10.85 Billion |
| 2024 | -15.93% | -4.25% | 1.34x | 2.79x | ₩-48.78 Billion |
| 2025 | 11.08% | 4.12% | 1.11x | 2.42x | ₩2.28 Billion |
Industry Comparison
This section compares Jeil Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $490,498,627,337
- Average return on equity (ROE) among peers: 5.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jeil Pharmaceutical Co Ltd (271980) | ₩253.26 Billion | 0.60% | 1.08x | $86.90 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.62 Billion | 7.70% | 0.48x | $98.05 Million |
| Yuhan Corp. (000100) | $1.12 Trillion | 8.27% | 0.18x | $3.84 Billion |
| Yuhan Corp Preferred (000105) | $2.36 Trillion | 8.22% | 0.36x | $45.29 Million |
| Yuyu Pharma (000220) | $82.83 Billion | 5.48% | 0.47x | $40.03 Million |
| Yuyu Pharma Inc (000225) | $78.29 Billion | 7.52% | 0.42x | $13.08 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $32.56 Million |
| Ildong Holdings Co Ltd (000230) | $349.98 Billion | 5.99% | 1.02x | $43.17 Million |
| Samil Pharm (000520) | $70.03 Billion | 11.32% | 0.65x | $108.19 Million |
| Donga Socio Holdings (000640) | $306.84 Billion | 8.70% | 1.30x | $379.59 Million |
| Jw Pharmac (001060) | $230.09 Billion | -10.98% | 1.49x | $349.95 Million |
About Jeil Pharmaceutical Co Ltd
Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, So… Read more